Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13095827 | 1.00 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3AOC3HSD17B10 | |
| SCHEMBL5289317 | 1.00 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3AOC3HSD17B10 | |
| SCHEMBL11164475 | 0.85 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL18071081 | 0.85 | GRIA1 (0.46) | SLC7A5CYP3A4SLC1A3AOC3GRIA2 | |
| SCHEMBL4854900 | 0.83 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL59078 | 0.83 | SLC7A5 (0.54) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL15349978 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL1065163 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL1539194 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM | |
| SCHEMBL5292853 | 0.81 | SLC7A5 (0.53) | SLC7A5CYP3A4SLC1A3HSD17B10PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1708 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (US) | 2026-04-16 | — | — | US | claimed |
| US-20250122239-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2025-04-17 | — | — | US | claimed |
| WO-2025069009-A1 | ROCK2 INHIBITORS IN THE TREATMENT OF OBESITY | GRAVITON BIOSCIENCE BV (NL) | 2025-04-03 | — | — | WO | claimed |
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| US-20220056077-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | RATNER, Cecilia (DK) | 2022-02-24 | — | — | US | claimed |
| US-6277819-B1 | GLUCAGON LIKE PEPTIDE1 (GLP-1) USED TO NORMALIZE BLOOD GLUCOSE IN DIABETIC PATIENTS | ELI LILLY AND COMPANY | 2001-08-21 | — | — | US | claimed |
| EP-1049486-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 2000-11-08 | — | — | EP | claimed |
| US-6133235-A | FOR TREATING MATURITY ONSET DIABETES MELLITUS IN MAMMALS, PARTICULARLY HUMANS | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | claimed |
| US-5981488-A | POLYPEPTIDE; ANTIDIABETIC AGENT | ELI LILLLY AND COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| US-5977071-A | COMPLEXES; ANTIDIABETIC AGENT | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | claimed |
| WO-1999029336-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1998043658-A1 | GLUCAGON-LIKE PEPTIDE-1 ANALOGS | ELI LILLY AND COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0869135-A1 | Glucagon-like peptide-1 analogs | ELI LILLY AND COMPANY (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0733644-A1 | Glucagon-like insulinotropic complexes, compositions and methods | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
| CN-1131674-A | Glucagon insulinotropic complexes, compositions and methods | LILLY CO ELI (US) | 1996-09-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | CBR1, CBR3, SIGMAR1 | SLC7A5 424/4885CYP3A4 59/4885SLC1A3 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.